Future of myelofibrosis treatment is moving beyond just JAK inhibition
Last Updated: Tuesday, March 29, 2022
This article showcases a presentation from the 26th Annual International Congress on Hematologic Malignancies on new treatment modalities for myelofibrosis, including BET, BCL-2/BCL-XL, PI3K, MDM2 inhibition and telomerase.
Advertisement
News & Literature Highlights